# SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

> **NCT01574274** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 240 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** SC-PEG
- **DRUG:** Oncaspar

## Key facts

- **NCT ID:** NCT01574274
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-06
- **Primary completion:** 2021-07
- **Final completion:** 2027-07-01
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01574274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01574274, "SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01574274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*